Compare AVIR & ACAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVIR | ACAA |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 355.6M |
| IPO Year | 2020 | 2026 |
| Metric | AVIR | ACAA |
|---|---|---|
| Price | $5.12 | $10.02 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.42 | N/A |
| AVG Volume (30 Days) | ★ 280.0K | 55.4K |
| Earning Date | 11-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $9.91 |
| 52 Week High | $6.45 | $10.24 |
| Indicator | AVIR | ACAA |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 53.86 |
| Support Level | $5.09 | $9.96 |
| Resistance Level | $5.76 | $10.24 |
| Average True Range (ATR) | 0.21 | 0.01 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 23.45 | 66.67 |
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Averin Capital Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.